CTSO - Company ID 0001175151
The table below shows Cytosorbents Corp's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $8.86M | $9.48M | $9.62M | $8.73M | $8.61M | $8.84M |
| Cost of revenue | $2.73M | $2.82M | $2.80M | $2.52M | $3.36M | $2.34M |
| Gross profit | $6.13M | $6.67M | $6.81M | $6.21M | $5.26M | $6.50M |
| R&D | $1.02M | - | - | $1.66M | $1.85M | $1.52M |
Cytosorbents Corp reported annual revenue of $37.06M for fiscal year 2025. That is up 4.1% from $35.59M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $9.53M (FY 2016) to $37.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $8.15M |
| $8.61M |
| $9.17M |
| $8.43M |
| $8.26M |
| $8.55M |
| Operating income | -$3.04M | -$2.86M | -$3.62M | -$3.89M | -$4.83M | -$3.57M |
| Income tax | $0.00 | -$401.00K | - | $0.00 | $0.00 | - |
| Net income | -$5.13M | -$3.17M | $1.95M | -$1.48M | -$2.77M | -$4.29M |
| EPS (diluted) | -$0.08 | -$0.05 | $0.03 | -$0.02 | -$0.05 | -$0.08 |